# Bristol-Myers Squibb

> Bristol-Myers Squibb is a VC fund backing Biotechnology and Health Care. See 115 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 115
- Last investment: Jul 2026
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
- X (Twitter): http://twitter.com/BMSNEWS
- Website: http://www.bms.com
- Facebook: https://www.facebook.com/BristolMyersSquibb

Bristol-Myers Squibb is a VC fund in New York focused on Biotechnology and Health Care. Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.

## Contacts

5 contacts available for Bristol-Myers Squibb. Shizune tracks 13 team members at Bristol-Myers Squibb. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bristol-myers-squibb?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 65 | 57% |
| Health Care | 44 | 38% |
| Therapeutics | 33 | 29% |
| Medical | 26 | 23% |
| Pharmaceutical | 15 | 13% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 32 | 28% |
| Series A | 24 | 21% |
| Grant | 18 | 16% |
| Series C | 13 | 11% |
| Post-IPO Equity | 5 | 4% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 63 | 55% |
| United Kingdom | 8 | 7% |
| India | 2 | 2% |
| Brazil | 2 | 2% |
| France | 2 | 2% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John damonti | Foundation President | 4 | https://shizune.co/investors/profile/john-damonti |
| Chris Boerner | Executive Vice President, Chief Commercialization Officer | 0 | https://shizune.co/investors/profile/chris-boerner |
| Debra Boyko-DeBrito | Director Content Management Solutions | 0 | https://shizune.co/investors/profile/debra-boyko-debrito |
| Donald J. Hayden, Jr. | President | 1 | https://shizune.co/investors/profile/donald-j-hayden-jr |
| Doug Bassett | SVP Informatics & Predictive Sciences | 0 | https://shizune.co/investors/profile/doug-bassett |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ratio Therapeutics | Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $70M | Series C | Jul 31, 2026 |  |
| Beeline Medicines | Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders. | $126.3M | Series A | Jun 30, 2026 |  |
| Precede Biosciences | Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M | Series B | Jan 12, 2026 |  |
| Link Cell Therapies | Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M | Series A | Dec 15, 2025 |  |
| BMS - Autoimmune Disease Drugs Business | BMS - Autoimmune Disease Drugs Business develops new therapies for autoimmune diseases. |  | Series A | Jul 28, 2025 |  |
| Dispatch Bio | Dispatch Bio helps create a world where all cancer patients can be cured. | $216M | Series A | Jul 23, 2025 |  |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M | Series B | May 27, 2025 |  |
| Foli Bio | Foli Bio is a precision medicine company transforming gastrointestinal disease diagnosis and drug development through Foli-seq, a novel non-invasive gut transcriptomics platform. By decoding exfoliated human RNA from stool, Foli-seq delivers deep mechanistic insight into inflammation, barrier dysfunction and treatment response. We are building ascalable insight engine that not only powers our internal diagnostic programs and partnered biomarker discovery across pharma pipelines but also serves as the foundation for AI-driven prediction, stratification, and patient monitoring. Ultimately, Foli-seq is positioned to evolve into a domain-specific foundation model for gut diseases. |  | Grant | Feb 28, 2025 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. | $92M | Series C | Jan 15, 2025 |  |
| Light Horse Therapeutics | Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future. | $62M | Series A | Jan 09, 2025 |  |

10 of 115 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 16 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 15 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 10 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 9 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 9 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bristol-Myers Squibb invest in?

Bristol-Myers Squibb invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 115 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bristol-Myers Squibb?

Public channels for Bristol-Myers Squibb include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bristol-Myers Squibb?

The team at Bristol-Myers Squibb includes John damonti (Foundation President), Chris Boerner (Executive Vice President, Chief Commercialization Officer) and Debra Boyko-DeBrito (Director Content Management Solutions), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co